Short answer
Monte Rosa Therapeutics, Inc. (GLUE) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $9M (down 61.3% year over year) with net income of −$43M.
Q2 2026 key financials · XBRL
- Revenue
- $9M
- −61.3% YoY · +113.0% QoQ
- Net income
- −$43M
- −253.0% YoY · +2.5% QoQ
- Operating margin
- -547.8%
Source: XBRL data from the Monte Rosa Therapeutics, Inc. (GLUE) Q2 2026 10-Q on SEC EDGAR. USD.
Monte Rosa Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added or changed risk factors provided; filing text contains financial statements and notes, not Item 1A disclosure
- Liquidity risk: accumulated deficit $565.1 million and six-month net loss $87.9 million
- Funding risk: cash, cash equivalents, and marketable securities $621.1 million expected to fund operations for at least 12 months
- Regulatory risk: product candidates require extensive clinical testing and regulatory approval before commercialization
- Operational risk: continued development requires significant additional capital, personnel, infrastructure, and compliance-reporting capabilities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Monte Rosa Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.